Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders?
- PMID: 11560947
- PMCID: PMC200940
- DOI: 10.1172/JCI14003
Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders?
Comment on
-
GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.J Clin Invest. 2001 Sep;108(6):887-94. doi: 10.1172/JCI12932. J Clin Invest. 2001. PMID: 11560958 Free PMC article.
References
-
- Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–492. - PubMed
-
- Purtilo DT, Strobach RS, Okano M, Davis JR. Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest. 1992;67:5–23. - PubMed
-
- Knowles DM, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85:552–565. - PubMed
-
- Orazi A, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol. 1997;107:419–429. - PubMed
-
- Mamzer-Bruneel M-F, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol. 2000;18:3622–3632. - PubMed
